Delivery Order SPE2DR25D1202-SPE2DR26F72DZ
- Not listed
- The Defense Logistics Agency awarded a $2,786.04 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Briviact 100 mg, with an ultimate completion date of October 20, 2025. This is a firm fixed price, non-competitive delivery order that serves the federal medical supply chain. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for military and veteran healthcare systems, with extensive experience...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Briviact 100mg tablets (60 count) with a ceiling value of $2,786.04. This is a firm fixed-price, non-competitive delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion pharmaceutical prime vendor agreement running through December 2026. The...
- The Defense Logistics Agency awarded a $7,166.00 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Briviact 100 mg on September 17, 2025, with an ultimate completion date of September 18, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and running through December 2026. The pharmaceutical product will be performed and...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on September 25, 2025, for 60 tablets of Briviact 100 mg with a ceiling value of $3,985.20. This firm fixed-price, non-set-aside delivery order is scheduled for completion by September 26, 2025, and represents a specific pharmaceutical supply need within the federal medical procurement system. The award is performed at the...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,072.23 for Briviact 100 mg tablets (60-count) with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and reflects AmerisourceBergen's role as a critical pharmaceutical supplier within the federal medical procurement system. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $5,677.12 to AmerisourceBergen Drug Corp for the supply of Briviact 100 mg tablets (60-count units) on August 18, 2025, with an ultimate completion date of August 19, 2025. This competitive, non-set-aside award employs firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a firm fixed price delivery order to AmerisourceBergen Drug Corp for Briviact 75 mg tablets (60-count units) valued at $1,945.50, with an ultimate completion date of October 22, 2025. This non-set-aside competitive award is a child order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The product will be delivered to AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $3,715.46 to AmerisourceBergen Drug Corp for the supply of Briviact 50 mg tablets (60-count units). The contract, which is not set-aside and utilizes firm fixed pricing, was awarded on November 3, 2025, with an ultimate completion date of November 4, 2025. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $9,365.70 to AmerisourceBergen Drug Corp for the supply of Briviact 50 mg tablets (60-count units). This firm fixed-price, non-competitive delivery order was executed on September 26, 2025, with an ultimate completion date of September 29, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child order under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Briviact 50 mg tablets (60-count units) with a ceiling value of $3,639.16. This is a firm fixed-price delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion global pharmaceutical support vehicle valued through December 2026. The award was competitively granted with no set-aside designation...
- SPE2DR25D1202Indefinite Delivery Contract
- SPE2DR25D1202-SPE2DR26F72DZDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,168.67 for 60 tablets of Briviact 50 mg on November 13, 2025, with completion expected by November 14, 2025. This firm fixed price delivery order represents a competitively awarded, non-set-aside procurement fulfilled by the pharmaceutical distributor's Corporate Office location in Conshohocken, Pennsylvania. The award is a child order under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vehicle through December 2026 that serves as a comprehensive global pharmaceutical support mechanism for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, continues to serve as a critical federal medical procurement vendor for the Defense Logistics Agency and related military healthcare systems. The delivery order for this neurological medication supports the company's established role supplying an extensive portfolio of pharmaceutical products—including brand-name and generic medications, vaccines, and specialized medical supplies—across multiple therapeutic domains to military and veteran healthcare customers worldwide. The competitively awarded status and firm fixed pricing structure reflect the vendor's demonstrated capability to meet federal procurement requirements through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 11/13/25 |